RxDoctor Payments Data

Eileen Kane

Family · Southbridge, MANPI 1700062262

Payments from drug & device makers

$2,285in general payments, 2019–2025

Across 121 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$888
  • AstraZeneca$547
  • Lilly USA, LLC$278
  • Astellas Pharma US Inc$120
  • Sumitomo Pharma America, Inc.$104
  • E.r. Squibb & Sons, L.L.C.$70
  • plus $278 from 10 others

What the payments were for

  • Food & beverage$2,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,285 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$285,657
Medicare patients
538
Services billed
3,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$95,984
OzempicSemaglutide45$49,397
TrulicityDulaglutide40$40,532
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$29,073
JanuviaSitagliptin Phosphate32$28,240
FarxigaDapagliflozin Propanediol25$20,659
MyrbetriqMirabegron21$12,576
Tresiba Flextouch U-100Insulin Degludec17$10,089
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$8,340
Rosuvastatin Calcium236$7,375
Arnuity ElliptaFluticasone Furoate27$6,602
Breo ElliptaFluticasone/Vilanterol14$6,242
Atorvastatin Calcium383$4,724
Albuterol Sulfate HfaAlbuterol Sulfate144$3,963
SynthroidLevothyroxine Sodium62$3,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$888$95,98485 claims
Lilly USA, LLCTrulicity$278$40,53240 claims
MerckJanuvia$21$28,24032 claims
AstraZenecaFarxiga$547$20,65925 claims
Astellas Pharma US IncMyrbetriq$120$12,57621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.

Other family in Southbridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →